Although localized prostate cancer is a heterogeneous disease, certain diagnostic features—pathology, imaging, and genetic profiling—can be helpful in categorizing patients into risk groups for adverse outcomes. At the NCCN 2022 Annual Conference, Julio M. Pow-Sang, MD, Chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discussed standard tools for risk stratification, including prostate-specific antigen (PSA), Gleason score, and T stage, and described newer modalities, such as MRI, prostate-specific membrane antigen (PSMA) PET/CT, genomic markers, and genetic testing. Dr. Pow-Sang also shared various management options for nonmetastatic prostate cancer, including active surveillance/observation, radiation therapy (RT), and surgery.
Centers for Disease Control and Prevention. U.S. Cancer Statistics Data Visualizations Tool, based on 2020 submission data (1999-2018). Accessed February 13, 2022. Available at: www.cdc.gov/cancer/dataviz
Schaeffer EM, Srinivas S, Antonarakis ES, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 3.2022. Accessed February 13, 2022. Available at NCCN.org
Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16–40.
Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18 F-DCFPyL in prostate cancer patients (OSPREY). J Urol 2021;206:52–61.
- Search Google Scholar
- Export Citation
, Pienta KJ , Gorin MA , Rowe SP A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18 F-DCFPyL in prostate cancer patients (OSPREY). J Urol 2021; 206: 52– 61. 10.1097/JU.0000000000001698 33634707